Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZNCF AstraZeneca	$134.75 -1.8%	$144.28	$120.64 ▼ $175.00	N/A	N/A	2,122 shs	1,084 shs
CMOPF Cosmo Pharmaceuticals	C$55.00	C$66.20	C$55.00 ▼ C$95.00	N/A	N/A	350 shs	N/A
CSPCY CSPC Pharmaceutical Group	C$3.13 -0.8%	C$2.55	C$2.15 ▼ C$3.82	N/A	N/A	30,277 shs	516 shs
OTSKY Otsuka	$23.64 +0.5%	$24.96	$19.30 ▼ $32.41	N/A	N/A	52,529 shs	19,747 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZNCF AstraZeneca	+1.10%	-1.83%	-6.99%	-0.51%	+1.40%
CMOPF Cosmo Pharmaceuticals	0.00%	0.00%	-12.41%	-23.61%	-27.63%
CSPCY CSPC Pharmaceutical Group	+0.16%	+12.68%	+34.26%	+44.06%	+2.44%
OTSKY Otsuka	+0.04%	-2.33%	-12.82%	-8.58%	+15.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZNCF AstraZeneca	0.3484 of 5 stars	0.0	2.0	1.7	0.0	1.2	0.8	0.0
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OTSKY Otsuka	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZNCF AstraZeneca	N/A	N/A	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A
OTSKY Otsuka	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZNCF AstraZeneca	N/A	N/A	N/A	N/A	N/A	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A	N/A
OTSKY Otsuka	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZNCF AstraZeneca	N/A	$0.82	165.13	∞	N/A	N/A	N/A	N/A	4/29/2025 (Estimated)
CMOPF Cosmo Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OTSKY Otsuka	N/A	$150.91	0.16	∞	N/A	N/A	N/A	N/A	4/30/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZNCF AstraZeneca	$2.80	2.08%	N/A	343.14%	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A
OTSKY Otsuka	$33.85	143.20%	N/A	22.43%	N/A

Latest OTSKY, AZNCF, CMOPF, and CSPCY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	AZNCF AstraZeneca		$2.10		2/19/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZNCF AstraZeneca	40.87%
CMOPF Cosmo Pharmaceuticals	N/A
CSPCY CSPC Pharmaceutical Group	N/A
OTSKY Otsuka	0.01%

Insider Ownership

Company	Insider Ownership
AZNCF AstraZeneca	N/A
CMOPF Cosmo Pharmaceuticals	N/A
CSPCY CSPC Pharmaceutical Group	N/A
OTSKY Otsuka	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZNCF AstraZeneca	83,500	N/A	N/A	Not Optionable
CMOPF Cosmo Pharmaceuticals	319	N/A	N/A	Not Optionable
CSPCY CSPC Pharmaceutical Group	23,500	N/A	N/A	Not Optionable
OTSKY Otsuka	34,388	N/A	N/A	Not Optionable

OTSKY, AZNCF, CMOPF, and CSPCY Headlines

Recent News About These Companies

Otsuka Holdings Corrects Disclosure on Taiho’s Acquisition of Araris Biotech

March 24, 2025 | tipranks.com

Otsuka Holdings Completes Major Share Repurchase

March 18, 2025 | tipranks.com

Taiho Pharmaceutical to Acquire Araris Biotech for $400 Million

March 17, 2025 | tipranks.com

Otsuka downgraded to Sell from Neutral at Goldman Sachs

February 26, 2025 | markets.businessinsider.com

Otsuka Holdings Reports Strong Financial Growth in FY2024

February 14, 2025 | tipranks.com

UBS raises Otsuka Holdings stock price target

September 11, 2024 | investing.com

OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q2 2024

August 23, 2024 | investorplace.com

Lundbeck: Good Near-Term Prospects, But Major Long-Term Unknowns

July 31, 2024 | seekingalpha.com

Otsuka ends development of late-stage Alzheimer's asset

May 22, 2024 | msn.com

Otsuka Holdings Co. Ltd. ADR

April 16, 2024 | wsj.com

Bayer looking at long shot 'Texas Two-Step' bankruptcy over Roundup - Bloomberg

March 14, 2024 | msn.com

Takeda gets FDA approval for eosinophilic esophagitis drug

February 12, 2024 | msn.com

Otsuka Holdings Co Ltd ADR (OTSKY)

January 23, 2024 | investing.com

Dong-A Otsuka holds blood donation event

August 30, 2023 | koreaherald.com

A 24-year-old former teacher at Yotsuya Otsuka "took spy photos of female students and forced them to make indecent remarks.

August 29, 2023 | msn.com

Renova inks virtual PPA with Otsuka Corp, Japan

August 24, 2023 | ijglobal.com

Otsuka Holdings GAAP EPS of ¥113.18, revenue of ¥448.34B; initiates Q2 and FY guidance

May 12, 2023 | msn.com

World War II memories haunt Julie Otsuka’s latest novel

March 12, 2023 | asahi.com

A Guide to Julie Otsuka's Books

January 31, 2023 | townandcountrymag.com

Andrew Carnegie Medal for Excellence awarded to Julie Otsuka, Ed Yong

January 30, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTSKY, AZNCF, CMOPF, and CSPCY Company Descriptions

AstraZeneca OTCMKTS:AZNCF

$134.75 -2.49 (-1.81%)

As of 12:29 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Cosmo Pharmaceuticals OTC:CMOPF

C$55.00 0.00 (0.00%)

As of 04/24/2025

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

CSPC Pharmaceutical Group OTCMKTS:CSPCY

C$3.13 -0.03 (-0.79%)

As of 12:08 PM Eastern

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Otsuka OTCMKTS:OTSKY

$23.64 +0.12 (+0.51%)

As of 03:59 PM Eastern

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products. In addition, the company offers IT solution services; adhesive tapes; flaky titanate and compounds; IV solutions; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; urinary tract health products; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. Otsuka Holdings Co., Ltd. was founded in 1921 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time